FDA Brief

Warning letters Drugs

FDA warning letter to

Medinatura New Mexico, Inc.

High riskIssued Dec 10, 2025Posted Dec 23, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.

What happened

FDA inspected the drug manufacturing facility in Albuquerque, New Mexico, from May 19 to May 23, 2025. Investigators found the company did not adequately test incoming components, including an active ingredient, relied on supplier certificates without validating them, lacked adequate cleaning validation for shared equipment, and had not validated production processes since 2007. FDA said these failures make the products adulterated, meaning they do not meet required drug quality standards.

What FDA found

  1. The company did not test each incoming component lot for identity, purity, strength, and quality, and did not validate suppliers’ certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Cleaning and maintenance procedures were inadequate; cleaning validation did not cover shared tablet equipment, hoses, or tanks, and equipment use and cleaning were not documented.

    21 CFR 211.67(b)
  3. Production and process controls were not adequately validated for homeopathic drug products, including products with potentially hazardous components.

    21 CFR 211.100(a)

What FDA wants

FDA tells Medinatura to correct the violations promptly and respond in writing within 15 working days with corrective actions, risk assessments, testing plans, and validation and cleaning program details. FDA also strongly recommends hiring a qualified CGMP consultant to audit the operation.

Who should pay attention

  • brands that buy or distribute drugs from this firm
  • other homeopathic drug manufacturers
  • suppliers and contract testing labs for drug components

This is a summary. Read the original letter on fda.gov.

Medinatura New Mexico, Inc.'s FDA history

Recalls in the last 12 months

Jan 14 Class I Medinatura New Mexico, inc.
Drug
ClearLife Allergy Nasal Spray, Extra Strength, 0.68 fl. oz. (20 mL) bottles, Distributed by: MediNatura, 10421 Research Rd., SE, Albuquerque, NM 87123, NDC 62795-4006-9, UPC 787647101887
Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.
Jan 14 Class I Medinatura New Mexico, inc.
Drug
ReBoost Nasal Spray, 0.68 fl. oz. (20 mL) bottles, Distributed by: MediNatura, 10421 Research Rd., SE, Albuquerque, NM 87123, NDC 62795-4005-9, UPC 787647101863
Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.

Full company page

Similar letters to other companies

  1. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  2. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk